Key facts
- It has raised $17.9M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Bpifrance, ILP Group, Alsace Business Angels, Angels Santé, Codexial Laboratoire Dermatologique — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for StemInov
- ·The full record, as it builds
Funding rounds
No funding rounds for StemInov are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StemInov
Developer of biomedicine and drugs intended to treat people with septic shock. The company is engaged in the clinical development of biomedicine using mesenchymal stem cells from the umbilical cord, enabling the medical community to optimize intensive care for complex syndromes.
- Sector
- Healthcare
- HQ
- Vandoeuvre-las-nancy, France
- Founded
- 2019
- Employees
- 4
- Website
- steminov.com/
- Ownership
- Privately Held (backing)
StemInov doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StemInov shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StemInov in its N-PORT filings yet. We sweep new filings monthly.